Pharmaceuticals News and Research

RSS

Amneal to launch AB-rated generic for Loestrin 24 Fe

Amneal Pharmaceuticals LLC will launch its AB-rated generic for Loestrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) 1 mg/20 mcg, 75 mg the first week of January 2014.

8 Nov 2013

Four-year study to develop targeted approach to psoriasis treatment

A world-leading taskforce led by The University of Manchester has begun work to create a new test to help medics work out which treatment plan is most likely to improve the disabling skin condition psoriasis, based on a patient's individual biological make-up.

8 Nov 2013

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

New Vortik technology has potential in pharmaceutical industry

The new Vortik technology allows different liquids to be mixed at the point of spray without altering the spray characteristics – opening up the possibility of new applications in agriculture, consumer and industrial products, and healthcare.

8 Nov 2013

People with gelatin allergy can have reaction from flu vaccinations

Do marshmallows make your tongue swell? Gummy bears make you itchy? If you've answered yes and are allergic to gelatin, you will want to take some precautions when getting the flu shot.

8 Nov 2013

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

Increased consumption of vegetable protein linked with prolonged survival among kidney disease patients

Increased consumption of vegetable protein was linked with prolonged survival among kidney disease patients in a new a study. The findings will be presented at ASN Kidney Week 2013 November 5-10 at the Georgia World Congress Center in Atlanta, GA.

8 Nov 2013

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

The statistic that you often hear is that 95% of diets fail, but in actual fact, emerging research is now showing that it’s around 70% of diets that fail. That means that around 30% of people who are losing weight are actually keeping it off. So we’re doing better now than we were doing in the past, but there’s still work to be done.

7 Nov 2013

Inhibition of heart protein reduces damage from heart attack, say researchers

The stop and start of blood flow to the heart during and after a heart attack causes severe damage to heart cells, reducing their capacity to function and potentially causing their death.

7 Nov 2013

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes and liver disease, as well as Asian people with T2D aged 65 years or older.

7 Nov 2013

ASU incorporates with seven research universities to establish Science and Technology Center

Arizona State University is teaming up with seven other research universities to establish a new Science and Technology Center (STC), sponsored by the National Science Foundation with an initial five-year, $25-million grant (extendable for another five years).

6 Nov 2013

PDL BioPharma closes financing transaction with Durata Therapeutics

PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

6 Nov 2013

New treatment option for patients with most difficult-to-treat forms of hepatitis C

A novel single-pill combination drug could present a new treatment option for patients with the most difficult-to-treat forms of hepatitis C, according to the results of a Phase 2 trial, published in The Lancet.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

Researchers use machine learning approach to accurately diagnose breast cancer

Software that can recognize patterns in data is commonly used by scientists and economics. Now, researchers in the US have applied similar algorithms to help them more accurately diagnose breast cancer.

6 Nov 2013

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of Fiscal 2014 (ended September 30, 2013).

6 Nov 2013

CHPA lends support for Restoring Access to Medication Act

The Consumer Healthcare Products Association is pleased to lend its support for the Restoring Access to Medication Act (S. 1647) introduced by U.S. Sens. Pat Roberts (R-Kan.) and Mary Landrieu (D-La.).

6 Nov 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.

6 Nov 2013

Jazz Pharmaceuticals announces third quarter financial results and updated 2013 guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter ended September 30, 2013 and updated 2013 financial guidance.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Pharmaceuticals News and Research

Amneal to launch AB-rated generic for Loestrin 24 Fe

Four-year study to develop targeted approach to psoriasis treatment

GHIT Fund makes new investments in potential treatments for malaria, tuberculosis and Chagas disease

New Vortik technology has potential in pharmaceutical industry

People with gelatin allergy can have reaction from flu vaccinations

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

Increased consumption of vegetable protein linked with prolonged survival among kidney disease patients

Diets and the famine reaction: an interview with Associate Professor Amanda Salis, University of Sydney

Inhibition of heart protein reduces damage from heart attack, say researchers

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

ASU incorporates with seven research universities to establish Science and Technology Center

PDL BioPharma closes financing transaction with Durata Therapeutics

New treatment option for patients with most difficult-to-treat forms of hepatitis C

Furiex reports financial and operating results for third quarter 2013

Researchers use machine learning approach to accurately diagnose breast cancer

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

CHPA lends support for Restoring Access to Medication Act

Depomed reports financial results for third quarter 2013

Jazz Pharmaceuticals announces third quarter financial results and updated 2013 guidance

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence